Gregory Abel.

Gregory Abel, MD, MPH

Professor of Medicine, HMS
Co-Chair, Dana-Farber Ethics Advisory Committee
Member, HMS Center for Bioethics

Gregory Abel, MD, MPH is an outcomes researcher and hematologic oncologist at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School. He helps run DFCI’s Older Adult Hematologic Malignancy (OHM) geriatric hematology research program, serves as Co-Chair of the DFCI Ethics Advisory Committee, and directs DFCI’s Clinical Ethics Service. The Abel research lab applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve their care. Dr. Abel is also interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through his work and collaboration with researchers in oncology, hematology, geriatrics, bioethics, and energy balance, he aims to ameliorate the impact of hematologic malignancies and their treatment from diagnosis to the end of life.

Publications View
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.
Authors: Authors: Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS.
Cancer
View full abstract on Pubmed
Public advertising by cancer centers: are more data needed?
Authors: Authors: Abel GA.
Ann Intern Med
View full abstract on Pubmed
Reply to quality control of bone marrow aspirates: additional steps toward a safer and more efficient procedure.
Authors: Authors: Odejide OO, Jacobson JO, Abel GA.
Cancer
View full abstract on Pubmed
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.
Authors: Authors: Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F.
Qual Life Res
View full abstract on Pubmed
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Authors: Authors: Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN.
Blood
View full abstract on Pubmed
Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Authors: Authors: Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL.
J Clin Oncol
View full abstract on Pubmed
Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life.
Authors: Authors: Abel GA, Klaassen R, Lee SJ, Young NL, Cannella L, Steensma DP, Efficace F.
Blood
View full abstract on Pubmed
A novel community-based delivery model to combat cancer disparities.
Authors: Authors: Waldman LT, Svoboda L, Young BF, Abel GA, Berlin S, Elfiky AA, Freedman RA, Drews M, Holland L, Lathan CS.
Healthc (Amst)
View full abstract on Pubmed
Using FastTrack to Implement an Academic Medical Center and Community Health Center Collaborative for Cancer Care Delivery.
Authors: Authors: Waldman LT, Bean W, Levine AL, Cohen-Bearak A, Phelps FA, Svoboda L, Freedman R, Elfiky A, Berlin S, Abel GA, Deutsch C, Lathan CS.
Healthc (Amst)
View full abstract on Pubmed
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
Authors: Authors: Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW.
Br J Haematol
View full abstract on Pubmed